Abstract
This article discusses recent developments in opioid pharmacology. Selective activity at different opioid receptors promises, but has not yet provided, a strong analgesic without opioid side-effects. The startling pharmacokinetic profile of the new esterasemetabolized intravenous opioid, remifentanil, is reflected in the rapid onset of effect and short, predictable recovery, independent of duration of infusion.
| Original language | English |
|---|---|
| Pages (from-to) | 105-106 |
| Number of pages | 2 |
| Journal | British Journal of Hospital Medicine |
| Volume | 57 |
| Issue number | 3 |
| Publication status | Published - 1997 |
ASJC Scopus subject areas
- Reviews and References (medical)